Navigation Links
Soon, a Vaccine That Could Keep All Types of Flu Away for Lifetime

British scientists are developing a flu vaccine that will give lifelong benefit to patients and it is also expected to fight anything from winter flu to bird flu .

Compared to traditional jabs, the new FLU-v vaccine is easier to make and can also be stocked for a global epidemic. "We expect one course of injections - probably of two a week apart - to give life-long immunity," the Daily Mail quoted Dr Stuart Robinson of the Buckinghamshire company PepTcell, which developed the vaccine, as saying.

The new vaccine is based on proteins that are common to all strains of the virus, which have not altered for about 60 years. The new vaccine makes immune system cells cytotoxic T cells to fight the virus, rather in bringing in antibodies.

Lab tests have shown that FLUv can save mice, for more than half the treated mice survived, while unvaccinated creatures died. "We are in real need of new types of vaccine. Anything that gives a more rapid response would be of great interest," Professor Hugh Pennington, emeritus professor at Aberdeen University, said.

Professor Malcolm McCrae of Warwick University said the vaccine could be a useful short-term measure against a totally new strain.

It is expected that human trials of FLU-v will start in 2008 and if they prove to be effective, it could be on the market in three to five years.


'"/>




Page: 1

Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
(Date:7/18/2008)...e-USNewswire/ -- Two consumer,groups today filed a...ent,on human embryonic stem cells held by the Wisc...r Watchdog, formerly The Foundation for Taxpayer a...on appealed to the U.S. Patent,Office,s Board of A...d,WARF,s patent after the two groups requested a r...
(Date:7/18/2008)...ectrum of the animal and human world will be exami...ongress, hosted by the International Society for B...l University in Ithaca., In addition to talks and...y sessions on: , Suzanne Alonzo, assistant prof...rsity, on "When Theory Meets Data: What We Don,t K...
(Date:7/18/2008)...ss campaign to raise awareness, of the importanc...cine compliance rates across the Uni.../ -- The COSHAR Foundation, a,nonprofit organizati...empowerment with a focus on minority and disadvant...areness Day on Saturday, July 19 in conjunction,wi...
(Date:7/18/2008)...dicine for psychiatric patients , , FRID...e found more evidence that a person,s genetic make... to the antidepressant Celexa (citalopram). , S...ound that variations in the serotonin transporter ...his drug, one of the family of medications known a...
Breaking Medicine News(10 mins):Health News:Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 3Health News:Gene Variations May Predict Antidepressant Response 2
...gy of enhancing communication with family members ...reatly reduce post-traumatic stress disorder, anx...cording to a study to be presented at the American...ference in San Francisco on Monday, May 21. The m...
...eley and Davis campuses of the University of Calif...ected with HIV successfully inactivates the free-...chnique - heating a glass jar of expressed breast ...or single burner - will provide hope that mothers...
...espond favorably to the drug temozolomide when use...treatment appears to work best in people missing a...ntific journal of the American Academy of Neurolog...ith low grade gliomas, a slow-growing type of brai...
...n diagnosed with breast cancer should either start...ey should continue exercising, for it will help th...archers analysed 500 women, who had survived breas...ctivity, and more specifically the intensity and a...
Other Medicine News:Health News:Improved Communication may Help to Accept the Death of Loved Ones With Poise 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 3Health News:Exercise may Help Breast Cancer Patients to Lead a Healthy Life 2
(Date:7/16/2008)...orts Pivotal Phase 2b Clinical Trials of First, ...f Cystic Fibrosis -, SOUTH PLAINFIELD, N.J. and B...tics, Inc. (PTC) and Cystic Fibrosis Foundation Th...f the Cystic Fibrosis Foundation, today,announced ...ort development,of PTC124, the PTC,s new investiga...
(Date:7/16/2008)...ly 16 /- MAP,Pharmaceutical...ve results,from a Phase 2 study evaluating the saf...in adult asthmatics were published in the July,iss...armaceuticals is,developing MAP0004, an orally inh... treatment for migraine., The study results, whic...
(Date:7/15/2008)...ewswire/ -- Abeome Corporation, a,Georgia-based bi...investment by Cato BioVentures and a collaboration...arch and development organization. The investment,...lopment of Abeome,s lead,ovarian cancer project., ...he development of,monoclonal antibodies and Abeome...
(Date:7/15/2008)...of Phase III Trials of Light Infusion Therapy,in H...Cancer and Phase I/II and Phase IIa Beni..., July 15 /- Light Sciences Oncology,...ight Infusion Therapy(TM),(Litx(TM)) to treat canc...as raised $40.1 million in a Series C round of fin...
Breaking Medicine Technology:PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124 2PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124 3PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124 4MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 2MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 3MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 4Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2Light Sciences Oncology Raises $40.1 Million in Series C Financing 2WuXi PharmaTech Completes Acquisition of AppTec 2919 1WuXi PharmaTech Completes Acquisition of AppTec 2919 2Survey 3A Massachusetts Employers Employees Paying Most for Health Care Plans 10689 1Survey 3A Massachusetts Employers Employees Paying Most for Health Care Plans 10689 2Survey 3A Massachusetts Employers Employees Paying Most for Health Care Plans 10689 3DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call 2917 1MITs McGovern Institute researchers awarded 248 5M to study brain basis of autism and dyslexia 10682 1MITs McGovern Institute researchers awarded 248 5M to study brain basis of autism and dyslexia 10682 2
...ENCE, Italy - 8 March 2007 - Cancer drug,developer...unces,positive initial findings from its second, c...cell lung cancer. , This 30-patient trial tested a...rboplatin and paclitaxel chemotherapy.,Investigato...of,patients showed disease stabilisation, while on...
...evelopment program of first-in-class CB1,antagonis...ion and,avoid image as life-style drug , BARCELONA...ce,firm La Merie S.L. reported today that Sanofi-A...ia (rimonabant) has at least,five competitors in c...rlier phases of R&D. While Acomplia received E...
Other Medicine Technology:Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 2Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 3Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 2Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 3
Take Performance to a Higher Level.
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC).
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic
...eal the arterial puncture site. Duett is the only ...e tissue tract with a flowable procoagulant. Usin...ulant - the Duett sealing device is designed to ra...nique in its ability to quickly seal the entire pu...
Medicine Products: